Through an agreement with National Health Service (NHS) and Sobi,( Swedish Orphan Biovitrium) people living with haemophilia A in the United Kingdom will have increased access to Elocta (efmoroctocog alfa) following a successful bid in the United Kingdom’s haemophilia A tender.
Efmoroctocog alfa is licensed by the European Commission in all age groups for treatment and prophylaxis (prevention) of bleeding in patients with haemophilia A . It is an extended half-life (EHL) therapy reimbursed by NHS England and as well, suitable for all age ranges and all severities.
“Today’s announcement is exciting news for the haemophilia A community in the UK. The agreement ensures continued and increased access to Elocta for people living with haemophilia A of all ages and all severities,” said Philip Wood, Head of Haematology and Head of Northern Europe at Sobi. Previously many people living with haemophilia A in the UK had restricted access to efmoroctocog alfa with a finite volume available under the previous agreement. The new agreement is an important step forward for haemophilia A treatment, allowing physicians to prescribe the most suitable therapies and tailor approaches for patients to protect against bleeds and joint damage.
Treatment guidelines recently published by the British Society for Haemotology (BSH) recommend that prophylactic treatment should be tailored to suit individual daily activity . EHL therapies have the potential to reduce injection frequency, increase treatment adherence, improve outcomes and potentially allow for a more active lifestyle .
The new framework agreement will commence on 1 July 2020 and will be operational for two years, with an option to extend for a further 24 months..